

EXHIBIT B

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 60772-PCT-US	U.S. Serial No. 09/768,872
									Applicant: Rina Aharoni et al.	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Filing Date: January 23, 2001	Group Art Unit
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
1	3	9	9	1	2	1	0	11/9/76	Shea	
2	4	1	2	9	6	6	6	12/12/78	Wizerkaniuk	
3	4	5	9	4	4	0	9	11/19/74	Hayashi et al.	
4	5	9	6	5	6	0	0	10/12/99	Sato, et al.	
5	6	0	2	4	9	8	1	2/15/00	Khankari, et al.	
6	6	1	6	2	8	0	0	12/19/00	Dolle, et al.	
7	6	3	6	2	1	6	1	3/26/02	Kontino, et al.	
8	6	5	1	4	9	3	8	2/4/03	Gad, et al.	
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation
										Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
47	Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94, 10821-10826									
48	Aharoni, et al., "Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", <u>Neurology</u> , 1997, Vol. 48, No. 3, A422									
49	Aharoni, et al., "Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1", <u>Journal of Neuroimmunology</u> , 1998, 91, 135-146									
50	Asakura et al., "A unique population of circulating autoantibodies promotes central nervous system remyelination", <u>Multiple Sclerosis</u> , 1998, 4, 217-221									
51	Asakura et al., "Targeting of IgM Antibodies to Oligodendrocytes Promotes CNS Remyelination", <u>The Journal of Neuroscience</u> , 1998, 18(19), 1700-1108									
52	Batchelor, et al., <u>Lancet</u> , 1980 1(8178):1107-9									
53	Bieber, et al., "Antibody-mediated remyelination: relevance to multiple sclerosis", <u>Multiple Sclerosis</u> , 2000, 6(2), S1-S5									
54	Bieber, et al., "Humoral autoimmunity as a mediator of CNS repair", <u>A Trends Guide to Neurodegenerative Disease and Repair/Review</u> , 2001, 24(11), S39-S44									
55	Bodanszky, M., "Principles of Peptide Synthesis," Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, 118-229									
56	Bornstein, "Clinical Experience: Hopeful Prospects In Multiple Sclerosis, <u>Hospital Practice</u> , 1992, Vol. 27, No. 5, pp. 135-158									
57	Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", <u>The Journal of Immunology</u> , 2000, 165, 7300-7307									
EXAMINER				DATE CONSIDERED						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Applicants : Rina Aharoni et al.
 Serial No. : 09/768,872
 Filed : January 23, 2001

Applicants: Rina Aharoni et al.
 Serial No.: 09/768,872
 Filed: January 23, 2001
Exhibit A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 60772-PCT-US	U.S. Serial No. 09/768,872	
									Applicant: Rina Aharoni et al.		
									Filing Date: January 23, 2001	Group Art Unit	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)											
U.S. PATENT DOCUMENTS											
Examiner Initial		Document Number				Date	Name		Class	Subclass	Filing Date if Appropriate
9	6	6	2	0	8	4	7	9/16/03	Konfino, et al.		
10	6	8	0	0	2	8	5	10/5/04	Yong & Chabot		
11	6	8	0	0	2	8	7	10/5/04	Gad, et al.		
12	6	8	4	4	3	1	4	1/18/05	Eisenbach-Schwartz, et al.		
13	6	9	3	9	5	3	9	9/6/05	Konfino et al.		
14	7	0	2	2	6	6	3	4/4/06	Gilbert et al.		
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country		Class	Subclass	Translation
										Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
58	Fatma, et al., <u>Swiss Med. Wkly</u> , 2003, 133:541-543										
59	Giuseppina, et al., <u>The Journal of Clinical Investigation</u> , April 2003, Vol. 111, No. 8, 1171-80										
60	Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, 12(6): 704-711										
61	Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group", <u>Neurology</u> , 45(7), 1268 (abstract)										
62	Kobayashi, et.al., <u>Clinical Exp. Immunology</u> , 1990, June 80(3):400-3										
63	Koreczyn, et al., "Safety profile Of copolymer 1: Analysis Of Cumulative Experience In The United States And Israel", <u>J. Neurol</u> , 1996, Vol. 243 (Suppl. 1), S23-S26										
64	Lombardi, et al., <u>J. Invest. Dermatol.</u> , 1999 July 113(1):107-10										
65	Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases," Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, <URL: http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM >										
66	Lymberi, et al., <u>Arch. Hellen. Med.</u> , 16(4), July-August 1999, 337-351										
67	McGavern, et al. "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?", <u>The Neuroscientist</u> , 1999, 5(1), 19-28										
EXAMINER					DATE CONSIDERED						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office								Atty. Docket No. 60772-Z-PCT-US	U.S. Serial No. 09/768,872	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Applicant: Rina Aharoni et al.		
										Filing Date: January 23, 2001	Group Art Unit	
U.S. PATENT DOCUMENTS												
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate
15		7	0	3	3	5	8	2	4/25/06	Yong et al.		
16		7	0	7	4	5	8	0	7/22/06	Gad et al.		
17		20	02	00	37	8	4	8	3/28/02	Einsenbach-Schartz et al.		
18		20	02	00	55	4	6	6	5/9/02	Aharoni et al.		
19		20	02	00	77	2	7	8	6/20/02	Yong et al.		
20		20	02	01	07	3	8	8	8/8/02	Vandenbark		
21		20	03	01	70	7	2	9	9/11/03	Klinger		
22		20	04	00	06	0	2	2	1/8/04	Strominger et al.		
FOREIGN PATENT DOCUMENTS												
		Document Number						Date	Country	Class	Subclass	Translation
												Yes
												No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
68	Merck Manual of Diagnosis and Therapy, <u>Merck Research Laboratories</u> , Whitehouse Section, N.J., 17 th Ed., 1999, 1300-1303, 1312-1317											
69	Pavelko, et al., "Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination", <u>The Journal of Neuroscience</u> , 1998 <u>18</u> (7), 2498-2505											
70	Pender, et al., Internal Med. Journal, 2002, 32: 554-563											
71	Pharmacia Biotech Directory, 1996, pages 340-341											
72	Physician's Desk Reference, 2000, Medical Economics Co. Inc., Montvale, NJ, 3115											
73	Racadot, et al., "Treatment of Multiple Sclerosis With Anti-CD4 Monoclonal Antibody", <u>J. of Autoimmunity</u> , 1993, Vol. 6, pp. 771-786											
74	Rodriguez, et al., "Immunoglobulins Reactive With Myelin Basic Protein Promote CNS Remyelination", <u>Neurology</u> , 1996, Vol. 46, pp. 538-545											
75	Rodriguez, et al., " <u>Neurological Therapeutics</u> , 1998, <u>15</u> (3): 245-250											
76	Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases", <u>Vaccine</u> , 1992, Vol. 10, Issue 14, 991-999											
77	Sridama, et al., <u>Arch Intern Med.</u> , 1987, 147:229-231											
78	Teva, et al., "Copolymer-1 Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , 1998, Vol. 23, No. 2, 213-214											
79	Ure, et al., "Polyreactive Antibodies To Glatiramer Acetate Promote Myelin Repair In Murine Model Of Demyelinating Disease", <u>FASEB Journal</u> , 2002, Vol. 16, pp. 1260-1262											
EXAMINER				DATE CONSIDERED								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 60772-Z-PCT-US	U.S. Serial No. 09/768,872	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Applicant: Rina Aharoni et al.		
									Filing Date: January 23, 2001	Group Art Unit	
U.S. PATENT DOCUMENTS											
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate	
23		20	05	00	19	3	2	2	1/27/05	Rodriguez et al.	
24		20	05	01	70	0	0	4	8/4/05	Rosenberger	
25		20	05	01	71	2	8	6	8/4/05	Konfino et al.	
26		20	05	02	56	0	4	6	11/17/05	Gad et al.	
27		20	06	00	52	5	8	6	3/9/06	Dolitzky	
28		20	06	01	22	1	1	3	6/8/06	Pinchasi et al.	
29		10	5	4	3	7	6	4	7/18/05	Aharoni et al.	
30		10	5	4	7	4	6	3	8/30/05	Pinchasi et al.	
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
80	Vandenbark, et al., "Specificity Of T Lymphocyte Lines For Peptide Of Myelin Basic Protein", <u>The J. Of Immunology</u> , 1985, Vol. 135, pp. 229-233										
81	Van Noort, et al., <u>International Review of Cytology</u> , 1996, 178: 127-205										
82	Wan, et al., <u>Human Immunology</u> , 2002, Apr. 63(4):301-10										
83	Warrington, et al., "Immunoglobulin-mediated CNS repair", <u>J. Allergy Clin. Immunol.</u> , 2001, S121-S125										
84	Warrington, et al., "Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis", <u>Neurobiology</u> , 2000, 97(12), 6820-6825										
85	Webster's II New Riverside University Dictionary, definition of "preventing", The Riverside Publishing Co., 1984, page 933										
86	Weilbach, et al., "Disease Modifying Treatments For Multiple Sclerosis: What Is On The Horizon?" <u>CNS Drugs</u> , 1999, Vol. 11, No. 2, pp. 133-167										
87	Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", <u>Journal of Neuroimmunology</u> , 2001, 119, 137-144										
88	Zhang, et al., "Murine Monoclonal Anti-Myelin Basic Protein (MBP) Antibodies Inhibit Proliferation And Cytotoxicity Of MBP-specific human T cell clones", <u>J. of Neuroimmunology</u> , 1989, Vol. 24, pp. 87-94										
89	"About Copaxone", Internet Article URL: http://www.mswatch.com/therapy/section.aspx?SectionId=789eabf5-3a07-4dff-a7ee-0d4ad138a6d										
90	URL: http://ntri.tamuk.edu/immunology/autoimmunity.html .										
EXAMINER				DATE CONSIDERED							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office										Atty. Docket No. 60772-Z-PCT-US	U.S. Serial No. 09/768,872	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)												Applicant: Rina Aharoni et al.		
												Filing Date: January 23, 2001	Group Art Unit	
U.S. PATENT DOCUMENTS														
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate	
31		10	5	5	6	4	5	4	11/17/05	Vollmer				
32		10	5	7	7	5	8	8	4/27/06	Rosenberger et al.				
33		11	2	2	8	8	5	0	9/14/05	Schwartz et al.				
34		11	3	3	6	2	5	1	1/20/06	Dolitzky				
35		11	3	7	3	7	9	4	3/9/06	Pinchasi				
FOREIGN PATENT DOCUMENTS														
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
36		01	0	8	5	7	9	7	11/15/01	WO				
37		02	0	7	6	5	0	3	10/3/02	WO				
38		03	0	4	8	7	3	5	6/12/03	WO				
39		0	3	7	8	2	4	6	6/18/90	Europe				
40		1	2	9	2	2	7	9	3/19/03	Europe				
41		3	9	3	0	7	3	3	3/28/91	Germany				
42		1	6	9	0	3	6	8	8/20/95	Russia				
43		1	4	6	9	8	2	6	11/20/95	Russia				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
EXAMINER					DATE CONSIDERED									
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 60772-Z-PCT-US	U.S. Serial No. 09/768,872
								Applicant: Rina Aharoni et al.	
								Filing Date: January 23, 2001	Group Art Unit
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
44	9 8 0 2 1 4	9/29/99	South Africa						
45	1 1 8 2 0 5 1	9/30/85	Soviet Union						
46	1 6 6 4 8 4 5	7/23/91	Soviet Union						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
EXAMINER		DATE CONSIDERED							
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>									